<DOC>
	<DOCNO>NCT00336349</DOCNO>
	<brief_summary>Effective treatment neuropathic foot pain diabetic patient important improve quality life . There many medication use reduce diabetic neuropathic pain , include anticonvulsant , anti-depressants analgesic , none universally satisfy . A previous study employ BOTOX® i.d . injection control trigeminal neuralgia , post-herpes neuralgia indicate BOTOX® effective control neuropathic pain . Intradermal injection BOTOX® dorsum foot diabetic effective control diabetes-associated polyneuropathic pain foot .</brief_summary>
	<brief_title>A Study Intra-dermal Injection Botulinum Toxin Type A Diabetic Neuropathic Foot Pain</brief_title>
	<detailed_description>Design : The present study single-center , randomize , double-blinded , cross-over study BOTOX® diabetic neuropathic foot pain . Pain Assessment : Subjective intensity neuropathic pain rat 100 mm visual analogue scale ( VAS , 0 = pain , 100 = unbearable pain ) . To assess somatosensory effect botulinum toxin , also perform aserial somatosensory evaluation upon bilateral medial ( L5 dermatome ) lateral ( S1 dermatome ) dorsum foot , bilateral medial calf ( L4 dermatome ) . Tactile threshold ( TT ) value assess von Frey filament , apply ascend descend order magnitude . The force require bend filament convert log unit comparison . Pain threshold ( PT ) static mechanical stimulus also determine von Frey filament upon test site evaluate severity cutaneous allodynia . All subject underwent subjective pain rating somatosensory evaluation ( TT PT ) baseline follow-up stage . Treatment : Treatments consist intradermal ( i.d ) . injection BOTOX® topical anesthesia randomly select 15 patient saline placebo 15 patient . Dose 0.5-1U/cm2 BOTOX® , total dose 50 U/foot . A follow-up visit assessment perform 1 , 4 8 , 12 week follow treatment previous test repeat . A cross-over injection Botox group saline group take 12th week repeat assessment 1 , 4 , 8 , 12 week . Analysis : Comparison treat foot non-treated foot base QVAS pain sensitivity test life quality questionnaire chi-square analysis . The summary proposal . Botox : 1. intradermal injection Topical anesthesia , EMLA 2 . 1 cc syringe 30-gauge needle 3 . 50 U/foot 4 . 12 points/foot ( 3×4 ) A total 30 case ( 15 Botox group , 15 saline group cross-over 12 week later )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1. type 2 diabetes medication diabetes＞ 3 year ( establish diagnosis , HbA1C &lt; 10 % ) 2. symptomatic polyneuropathy ( stock distribution tingle pain ) 3. stable satisfactory effect drug diabetic neuropathic foot pain ( stable effect medication 6 month ) 4. fitness polyneuropathy Nerve Conduction Velocity ( NCV ) criteria 5. willing able give write informed consent . 6. willing able complete entire study course comply study direction . 1 . Injection possible due physiologic barrier . 2 . Subject pregnant lactating . 3 . Females childbearing age use reliable method avoid pregnancy . 4 . Significant medical psychiatric disease . 5 . Any condition may put subject increase risk exposure BOTOX® , include 6. diagnosed myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , disease might interfere neuromuscular function . 7 . Use aminoglycoside antibiotic , curarelike agent , agent might interfere neuromuscular function . 8 . Acute medication overuse investigator 's best judgment . 9 . Alcohol drug abuse . 10 . Heavy smoker 11 . Infection skin problem injection site . 12 . Known allergy sensitivity study medication component . 13 . Injections anesthetic steroid study target muscle within one month prior day injection 14 . Concurrent participation another clinical trial within 30 day begin study . 15 . Previous use botulinum toxin . ( Types A B ) 16 . Profound atrophy excessive weakness muscle target area ( ) injection . 17 . Evidence peripheral artery occlusion 18 . Evidence liver renal function impairment 19 . Evidence old stroke</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>neuropathic pain</keyword>
</DOC>